Jacqueline N. Crawley, Ph.D.
Journal Articles
2014 Kazdoba TM, Leach PT, Silverman JL, Crawley JN. Modeling fragile X syndrome in
the Fmr1 knockout mouse. Intractable Rare Dis Res. Nov;3(4):118-33.
2014 Bales KL, Solomon M, Jacob S, Crawley JN, Silverman JL, Larke RH, Sahagun E,
Puhger KR, Pride MC, Mendoza SP. Long-term exposure to intranasal oxytocin in a
mouse autism model, Translational Psychiatry 4:e480.
2015 Flannery BM, Silverman JL, Bruun DA, Puhger KR, McCoyc MR, Hammock BD,
Crawley JN, Lein PJ. Behavioral assessment of NIH Swiss mice acutely intoxicated
with tetramethylenedisulfotetramine. Neurotoxicology and Teratology 47:36-45.
2015 Ellegood J, Anagnostou E, Babineau B, Crawley JN, Lin L, Genestine M, DiCiccoBloom E, Lai J, Foster J, Peñagarikano O, Geschwind D, Pacey L, Hampson D,
Laliberté C, Mills A, Tam E, Osborne L, Kouser M, Espinosa-Becerra F, Xuan Z,
Powell C, Raznahan A, Robins D, Nakai N, Nakatani J, Takumi T, van Eede M, Kerr
T, Muller C, Blakely R, Veenstra-VanderWeele J, Henkelman M, Lerch J. Clustering
autism - using neuroanatomical differences in 26 mouse models to gain insight into
the heterogeneity. Molecular Psychiatry 20:1.
2015 Silverman JL, Pride MC, Hayes JE, Puhger KR, Butler-Struben H, Baker S, Crawley
JN. GABAB receptor agonist R-baclofen reverses social deficits and reduces
repetitive behavior in two mouse models of autism. Neuropsychopharmacology 40:
2015 Yang M, Mahrt EJ, Lewis F, Foley G, Portmann T, Dolmetsch RE, Portfors CV,
Crawley JN. 16p11.2 deletion syndrome mice display sensory and ultrasonic
vocalization deficits during social interactions. Autism Research, Feb 7. doi:
10.1002/aur.1465. [Epub ahead of print].
2015 Yang M, Lewis F, Foley G, Crawley JN. In tribute to Bob Blanchard: Divergent
behavioral phenotypes of 16p11.2 deletion mice reared in same-genotype versus
mixed-genotype cages. Physiol Behav. 2015 Apr 15. pii: S0031-9384(15)00230-9. doi:
10.1016/j.physbeh.2015.04.023. [Epub ahead of print].
Abstracts and Presentations
2014 RIKEN Brain Research Institute Summer Program, Tokyo, Japan, “Behavioral
phenotyping strategies for mutant mouse models of neuropsychiatric disorders,” July
2014 Seminars in Translational Neuroscience, Center for Translational Medicine, University
of Missouri School of Medicine, Jefferson City, MO, “Behavioral phenotyping
strategies for mutant mouse models of neurodevelopmental disorders, October 6th.
2014 Keynote Lecture, The Autism Conference, Thompson Center for Autism and
Neurodevelopmental Disorders, University of Missouri, Columbia, MO, “Mouse models
of autism to test hypotheses about causes and discover effective therapeutics,”
October 7th.
2014 Study Group, American College of Neuropsychopharmacology annual meeting,
Phoenix, AZ, “Developing methods for cross-species research on impairing irritability
in children,” December 9th.
2015 Distinguished Medical Scientist Lecture, University of California Irvine, Irvine, CA,
“Discovering pharmacological treatments for the diagnostic symptoms of autism using
mouse models,” January 9th.
2015 Distinguished Lecture, CHI Health, Creighton University School of Medicine, Omaha,
Nebraska, “Mouse models of autism to test hypotheses about causes,” January 28th.
2015 Neuroscience Seminar, University of Wyoming, Laramie, WY, “Mouse models of
autism to test hypotheses about causes and discover treatments,” March 28th.
2015 International Meeting for Autism Research, Salt Lake City, UT, “Introduction and
overview of IMFAR 2015 scientific program,” May 13.
2015 Symposium Lecture, International Behavioral Neuroscience Society, Victoria, British
Columbia, Canada, “Channeling Bob Blanchard: Social behavior assays for mouse
models of autism,” June 6.
2015 Keynote Lecture, Mouse Phenotyping Symposium, Institut du Cerveau et de la Moelle,
Paris, France, “Behavioral phenotyping strategies for mouse models of
neuropsychiatric and neurodevelopmental disorders,” June 15.
Research Funding
Simons Foundation SFARI #204340JC. (Dolmetch R, Crawley JN: Co-PIs) 3/1/2012 –
2/28/2015. 16p11.2 Deletion Mice: Autism-Relevant Phenotypes and Treatment Discovery.
The goal of this project was the initial comprehensive characterization of behavioral
phenotypes of 16p11.2 deletion mice. No overlap with the present application, which focuses
on genetic backgrounds in high and low vocalizing subsets of 16p11.2 heterozygotes.
NINDS 1U54NS079202-01.CounterAct Center: Novel anticonvulsant and neuroprotective
therapies for TETS and OP intoxication. (Lein P: PI, Crawley JN: Co-Investigator) 9/1/2012 –
8/31/17. The goal of this project is the evaluation of long-lasting effects of seizure-inducing
environmental toxins on cognitive, anxiety-related and depression-related behaviors in mice
and rats.
Simons Foundation SFARI #201223539. Characterization of brain and behavior in 7q11.23
duplication syndrome. (Osborne L, Crawley JN: Co-PIs) 01/01/2013 – 12/31/2015. The goal
of this project is the investigation of behavioral phenotypes of 7q11.23 duplication mice.
Autism Speaks Targeted Proposal (Crawley JN, Sahin M, Jones: Co-PIs) 9/1/20138/31/2016. Preclinical Autism Consortium for Therapeutics (PACT). The goal of this project is
to phenotype autism-relevant behaviors and physiology in four genetic mouse models of
autism, to generate a platform for therapeutic discovery.
NIH R01 Convergent Synaptic Mechanisms in Neurodevelopmental Disorders. (Crawley JN,
Gall C, Lynch G: Co-PIs) 9/1/2013-8/31/2018. The goal of this project is to discover common
downstream mechanisms in four mouse models of neurodevelopmental disorders with
cognitive impairment.
NICHD U54. Intellectual and Developmental Disabilities Research Center (Abbeduto L: PI,
Crawley JN: Director, Rodent Behavior Core E) 9/24/2013-6/30/2018. The goal of this project
is to develop and lead a Rodent Behavioral Core facility for MIND Institute and UC Davis
users working on mouse and rat models of neurodevelopmental disorders.
Community Service
Core E Director, IDDRC Executive Committee, MIND Institute
Member, Executive Committee, MIND Institute

Journal Articles Crawley JN Intractable Rare Dis Res